Approval · Notice of Compliance 37770 · 2026
IMDELLTRA: Notice of Compliance 37770
Issued June 25, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37770
- Date
- June 25, 2026
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Indication : IMDELLTRA (tarlatamab for injection) is indicated for: the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IMDELLTRA | Not yet assigned | — |
Medicinal ingredients
- TARLATAMAB 1 MG per VIAL
- TARLATAMAB 10 MG per VIAL